Effect of silymarin on hepatic function of patients with unresectable hepatocellular carcinoma after transcatheter hepatic arterial chemoembolization

Chi-Ming Lee, Ting-Kai Leung, Chun Chao Chang, Yu Cheng Kuo, Jeng Fong Chiou, Hung Jung Wang, Ya Yen Chen

Research output: Contribution to journalArticle

Abstract

Transcatheter hepatic arterial chemoembolization (TACE) is common treatment for unresectable hepatocellular carcinoma. Silymarin, derived from milk thistle, is widely used internationally for chronic liver disease. Some Taiwanese physicians prescribe silymarin as a hepatoprotective agent after TACE, although there is no evidence on its efficacy in this setting. Retrospectively compare two groups of patient undergoing TACE at our institution: 111 given silymarin postoperatively and 133 who underwent the same procedure and received similar postoperative care but were not given silymarin. The postoperative liver function was evaluated. Patients prescribed silymarin took 280 mg orally daily for two weeks. Liver function tests were checked at baseline and on post-TACE days 2, 4, and 6 and weeks 2-5. Groups were comparable for age, gender, and Child-Pugh class. There were no significant differences between the two groups at different time points in serum levels of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total bilirubin, albumin and lactate dehydrogenase. Oral silymarin did not accelerate recovery of hepatic function following TACE; there is no basis for its use in this setting.

Original languageEnglish
Pages (from-to)137-141
Number of pages5
JournalChinese Journal of Radiology
Volume33
Issue number3
Publication statusPublished - Sep 2008

Fingerprint

Silymarin
Hepatocellular Carcinoma
Liver
Milk Thistle
Postoperative Care
Liver Function Tests
Recovery of Function
Aspartate Aminotransferases
Alanine Transaminase
L-Lactate Dehydrogenase
Bilirubin
Alkaline Phosphatase
Liver Diseases
Albumins
Chronic Disease
Physicians
Serum

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Effect of silymarin on hepatic function of patients with unresectable hepatocellular carcinoma after transcatheter hepatic arterial chemoembolization. / Lee, Chi-Ming; Leung, Ting-Kai; Chang, Chun Chao; Kuo, Yu Cheng; Chiou, Jeng Fong; Wang, Hung Jung; Chen, Ya Yen.

In: Chinese Journal of Radiology, Vol. 33, No. 3, 09.2008, p. 137-141.

Research output: Contribution to journalArticle

@article{70593e36fb1d4d7a8e96b20d351f2dd1,
title = "Effect of silymarin on hepatic function of patients with unresectable hepatocellular carcinoma after transcatheter hepatic arterial chemoembolization",
abstract = "Transcatheter hepatic arterial chemoembolization (TACE) is common treatment for unresectable hepatocellular carcinoma. Silymarin, derived from milk thistle, is widely used internationally for chronic liver disease. Some Taiwanese physicians prescribe silymarin as a hepatoprotective agent after TACE, although there is no evidence on its efficacy in this setting. Retrospectively compare two groups of patient undergoing TACE at our institution: 111 given silymarin postoperatively and 133 who underwent the same procedure and received similar postoperative care but were not given silymarin. The postoperative liver function was evaluated. Patients prescribed silymarin took 280 mg orally daily for two weeks. Liver function tests were checked at baseline and on post-TACE days 2, 4, and 6 and weeks 2-5. Groups were comparable for age, gender, and Child-Pugh class. There were no significant differences between the two groups at different time points in serum levels of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total bilirubin, albumin and lactate dehydrogenase. Oral silymarin did not accelerate recovery of hepatic function following TACE; there is no basis for its use in this setting.",
author = "Chi-Ming Lee and Ting-Kai Leung and Chang, {Chun Chao} and Kuo, {Yu Cheng} and Chiou, {Jeng Fong} and Wang, {Hung Jung} and Chen, {Ya Yen}",
year = "2008",
month = "9",
language = "English",
volume = "33",
pages = "137--141",
journal = "Chinese Journal of Radiology",
issn = "1018-8940",
publisher = "中華民國放射線醫學會",
number = "3",

}

TY - JOUR

T1 - Effect of silymarin on hepatic function of patients with unresectable hepatocellular carcinoma after transcatheter hepatic arterial chemoembolization

AU - Lee, Chi-Ming

AU - Leung, Ting-Kai

AU - Chang, Chun Chao

AU - Kuo, Yu Cheng

AU - Chiou, Jeng Fong

AU - Wang, Hung Jung

AU - Chen, Ya Yen

PY - 2008/9

Y1 - 2008/9

N2 - Transcatheter hepatic arterial chemoembolization (TACE) is common treatment for unresectable hepatocellular carcinoma. Silymarin, derived from milk thistle, is widely used internationally for chronic liver disease. Some Taiwanese physicians prescribe silymarin as a hepatoprotective agent after TACE, although there is no evidence on its efficacy in this setting. Retrospectively compare two groups of patient undergoing TACE at our institution: 111 given silymarin postoperatively and 133 who underwent the same procedure and received similar postoperative care but were not given silymarin. The postoperative liver function was evaluated. Patients prescribed silymarin took 280 mg orally daily for two weeks. Liver function tests were checked at baseline and on post-TACE days 2, 4, and 6 and weeks 2-5. Groups were comparable for age, gender, and Child-Pugh class. There were no significant differences between the two groups at different time points in serum levels of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total bilirubin, albumin and lactate dehydrogenase. Oral silymarin did not accelerate recovery of hepatic function following TACE; there is no basis for its use in this setting.

AB - Transcatheter hepatic arterial chemoembolization (TACE) is common treatment for unresectable hepatocellular carcinoma. Silymarin, derived from milk thistle, is widely used internationally for chronic liver disease. Some Taiwanese physicians prescribe silymarin as a hepatoprotective agent after TACE, although there is no evidence on its efficacy in this setting. Retrospectively compare two groups of patient undergoing TACE at our institution: 111 given silymarin postoperatively and 133 who underwent the same procedure and received similar postoperative care but were not given silymarin. The postoperative liver function was evaluated. Patients prescribed silymarin took 280 mg orally daily for two weeks. Liver function tests were checked at baseline and on post-TACE days 2, 4, and 6 and weeks 2-5. Groups were comparable for age, gender, and Child-Pugh class. There were no significant differences between the two groups at different time points in serum levels of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total bilirubin, albumin and lactate dehydrogenase. Oral silymarin did not accelerate recovery of hepatic function following TACE; there is no basis for its use in this setting.

UR - http://www.scopus.com/inward/record.url?scp=56749097836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56749097836&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:56749097836

VL - 33

SP - 137

EP - 141

JO - Chinese Journal of Radiology

JF - Chinese Journal of Radiology

SN - 1018-8940

IS - 3

ER -